Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the safety, tolerability, and feasibility of adult allogeneic bone marrow–derived mesenchymal precursor cells (MPCs) in type 2 diabetes inadequately controlled with metformin either alone or with one additional oral antidiabetic agent. RESEARCH DESIGN AND METHODS: The study was a dose-escalating randomized placebo-controlled trial assessing one intravenous (IV) infusion of MPCs (rexlemestrocel-L; Mesoblast Inc.) 0.3 × 106/kg (n = 15), 1.0 × 106/kg (n = 15), or 2.0 × 106/kg (n = 15) or placebo (n = 16). Study duration was 12 weeks. RESULTS: Subjects (21 women, 40 men) with a mean ± SD baseline HbA1c 8.3 ± 1.0% (67 ± 10.9 mmol/mol), BMI 33.5 ± 5.5 kg/m2, and diabetes duration 10.1 ± 6.0 years were enrolled at 18 U.S. sites. No acute adverse events (AEs) were associated with infusion. No serious AEs, serious hypoglycemia AEs, or discontinuations due to AEs over 12 weeks were found. No subjects developed donor-specific anti-HLA antibodies or became sensitized. The safety profile was comparable among treatment groups. Compared with placebo, a single IV infusion of rexlemestrocel-L reduced HbA1c at all time points after week 1. The adjusted least squares mean ± SE dose-related differences in HbA1c from placebo in the rexlemestrocel-L groups ranged from −0.1 ± 0.2% (−1.1 ± 2.2 mmol/mol) to −0.4 ± 0.2% (4.4 ± 2.2 mmol/mol) at 8 weeks and from 0.0 ± 0.25% to −0.3 ± 0.25% (−3.3 ± −2.7 mmol/mol) at 12 weeks (P < 0.05 for 2.0 × 106/kg dose at 8 weeks). The clinical target HbA1c <7% (53 mmol/mol) was achieved by 33% (5 of 15) of the subjects who received the 2.0 × 106/kg dose vs. 0% of those who received placebo (P < 0.05). CONCLUSIONS: This short-term study demonstrates the safety and feasibility of up to 246 million MPCs in subjects with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 1×
“inflammatory effect of rexlemestrocel-L resulting in improved glycemic control is suggested by similar mild effects reported with canakinumab and anakinra (26,27).”
ResultMechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436 · cited 2×
“The secretory activity and subsequent paracrine effects of these cells in vivo is central to their clinical potential (18) because little evidence suggests that they engraft when administered systemically (20).”
BackgroundMesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816 · cited 1×
“The anti-inflammatory properties of adult bone marrow–derived mesenchymal lineage cells (11) may potentially address a novel pathway contributing to the pathogenesis of type 2 diabetes, as suggested by the observed effects of these cells on hyperglycemia in preclinical models of diabetes (12,13) and pilot clinical stu…”
BackgroundTargeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., & Thuren, T. (2012) · Circulation · doi:10.1161/circulationaha.112.122556 · Cited by 530
Cited by
Kabat, M., Bobkov, I., Kumar, S., & Grumet, M. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0202 · Cited by 444
Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease
Gilbert, R. E. (2017) · Diabetes · doi:10.2337/db16-0796 · Cited by 362
Thompson, M., Mei, S. H. J., Wolfe, D., Champagne, J., Fergusson, D., Stewart, D. J., Sullivan, K. J., Doxtator, E., Lalu, M., English, S. W., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.100249 · Cited by 283
Bhansali, S., Dutta, P., Kumar, V., Yadav, M. K., Jain, A., Mudaliar, S., Bhansali, S., Sharma, R. R., Jha, V., Marwaha, N., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0275 · Cited by 126
“However, this study had a follow-up of only 3 months [14].”
InfluentialYazhen, Z., Wenyi, C., Bing, F., & Hongcui, C. (2020) · Aging and disease · doi:10.14336/ad.2019.0421 · Cited by 82
“have shown that patients with T2DM have reduced exogenous insulin requirements after bone marrowderived MSC treatment [23, 47].”
BackgroundRahim, F., Arjmand, B., Shirbandi, K., Payab, M., & Larijani, B. (2018) · Non-coding RNA Investigation · doi:10.21037/sci.2018.11.01 · Cited by 30
Engineering islets from stem cells: The optimal solution for the treatment of diabetes
Du, S., Li, Y., Geng, Z., Zhang, Q., Buhler, L. H., Gonelle-Gispert, C., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869514 · Cited by 9
Wang, Y., Yu, H., Tang, H., Zhu, R., Shi, Y., Xu, C., Li, Y., Wang, H., Chen, Y., Shen, P., et al. (2023) · Regenerative Therapy · doi:10.1016/j.reth.2023.07.007 · Cited by 3
Metadata
- Authors
- Skyler, J. S., Fonseca, V. A., Segal, K. R., & Rosenstock, J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-07-07
- Volume
- 38
- Issue
- 9
- Pages
- 1742-1749
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2130155157
- Cited by
- 118
- References
- 10
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.